

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Karl Gunnar Bjursell *et al.*

Serial No.: 10/599,588

Filed: October 2, 2006

For: NEW METHOD

Group Art Unit: 1641

Examiner: Unknown

Atty. Dkt. No.: EPCL:013US

Confirmation No.: 1186

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below.

March 21, 2007

Date

Steven L. Highlander

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to

be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/EPCL:013US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 21, 2007

Form PTO-1449 (modified)		Att. Docket No.: EPC1:013US	Serial No.: 10/599,588
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT		Applicant: Karl Gunnar Bjursell <i>et al.</i>	
(Use several sheets if necessary)		Filing Date: October 2, 2006	Group: 1641
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-2	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	BI	EP 0640620	07/01/93	Europe	English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Auge <i>et al.</i> , "Pancreatic bile salt-dependent lipase induces smooth muscle cells proliferation," <i>Circulation</i> , 108:86-91, 2003.
	C2	Bengtsson <i>et al.</i> , "Transcriptional regulation of the human carboxyl ester lipase gene in THP-1 monocytes: An E-box required for activation binds upstream stimulatory factors 1 and 2," <i>Biochem. J.</i> , 365:481-488, 2002.
	C3	Brodt-Eppley <i>et al.</i> , "Plasma cholesterol esterase level is a determinant for an atherogenic lipoprotein profile in normolipidemic human subjects," <i>Biochim Biophys. Acta</i> , 1272:69-72, 1995.
	C4	Bruneau <i>et al.</i> , "Circulating bile salt-dependent lipase originates from the pancreas via intestinal transcytosis," <i>Gastroenterology</i> , 124:470-480, 2003.
	C5	Bruneau <i>et al.</i> , "Lectin-like Ox-LDL receptor is expressed in human INT-407 intestinal cells: Involvement in the transcytosis of pancreatic bile salt-dependent lipase," <i>Mol. Biol Cell</i> , 14:2861-2875, 2003.
	C6	Bruneau <i>et al.</i> , "The affinity binding sites of pancreatic bile salt-dependent lipase in pancreatic and intestinal tissues," <i>J. Histochem. Cytochem.</i> , 48:267-276, 2000.
	C7	Bruneau <i>et al.</i> , "Transcytosis of pancreatic bile salt-dependent lipase through human Int407 intestinal cells," <i>Exp. Cell Res.</i> , 271:94-108, 2001.
	C8	Caillol <i>et al.</i> , "Pancreatic bile salt-dependent lipase activity in serum of normolipidemic patients," <i>Lipids</i> , 32:1147-1153, 1997.

25748205.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Att. Docket No.: EPCL:013US	Serial No.: 10/599,588
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT		Applicant: Karl Gunnar Bjursell <i>et al.</i>	
(Use several sheets if necessary)		Filing Date: October 2, 2006	Group: 1641
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Camarota <i>et al.</i> , "Carboxyl ester lipase cofractionates with scavenger receptor B1 in hepatocyte lipid rafts and enhances selective uptake and hydrolysis of cholesteryl esters from HDL3," <i>J. Biol. Chem.</i> , 279:27599-27606, 2004.
	C10	Falt <i>et al.</i> , "Do human bile salt stimulated lipase and colipase-dependent pancreatic lipase share a common heparin-containing receptor?" <i>Archives Biochem. Biophys.</i> , 386:188-194, 2001.
	C11	Hui and Howles, "Carboxyl ester lipase: Structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis," <i>J. Lipid Res.</i> , 43:2017-2030, 2002.
	C12	Kirby <i>et al.</i> , "Bile salt-stimulated carboxyl ester lipase influences lipoprotein assembly and secretion in intestine: a process mediated via ceramide hydrolysis," <i>J. Biol. Chem.</i> , 277:4104-4109, 2002.
	C13	Li and Hui, "Modified low density lipoprotein enhances the secretion of bile salt-stimulated cholesterol esterase by human monocyte-macrophages. Species-specific difference in macrophage cholesteryl ester hydrolase," <i>J. Biol. Chem.</i> , 272:28666-28671, 1997.
	C14	Lombardo, "Bile salt-dependent lipase: its pathophysiological implications," <i>Biochim. Biophys. Acta</i> , 1533:1-28, 2001.
	C15	Moriwaki <i>et al.</i> , "Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 18:1541-1547, 1998.
	C16	Rebai <i>et al.</i> , "In vitro angiogenic effects of pancreatic bile salt-dependent lipase," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 25:359-364, 2005.
	C17	Sawamura <i>et al.</i> , "An endothelial receptor for oxidized low-density lipoprotein," <i>Nature</i> , 386:73-77, 1997.
	C18	Shamir <i>et al.</i> , "Pancreatic carboxyl ester lipase: a circulating enzyme that modifies normal and oxidized lipoproteins in vitro," <i>J. Clin. Invest.</i> , 97:1696-1704, 1996.
	C19	Shamir <i>et al.</i> , "Serum Levels of Bile Salt-Stimulated Lipase and Breast Feeding," <i>J. Pediatric Endocrin. Metab.</i> , 16:1289-1294, 2003.

25748205.1

EXAMINER:

DATE CONSIDERED:

EXAMINER. INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.